Growth Metrics

Novartis Ag (NVS) Enterprise Value Growth (3y) (2012 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 50.70%
Sep 30, 2025 253.57%
Jun 30, 2025 -23.48%
Mar 31, 2025 26.85%
Dec 31, 2024 57.51%
Sep 30, 2024 -52.38%
Jun 30, 2024 -16.25%
Dec 31, 2023 -7.47%
Sep 30, 2023 -375.24%
Jun 30, 2023 -26.30%
Mar 31, 2023 26.26%
Dec 31, 2022 -19.32%
Sep 30, 2022 -28.77%
Jun 30, 2022 35.48%
Mar 31, 2022 44.24%
Dec 31, 2021 -22.61%
Sep 30, 2021 24.42%
Jun 30, 2021 16.92%
Mar 31, 2021 -58.74%
Dec 31, 2020 -6.81%
Sep 30, 2020 -26.62%
Jun 30, 2020 7.04%
Mar 31, 2020 -39.45%
Dec 31, 2019 -15.20%
Sep 30, 2019 -22.50%
Jun 30, 2019 -28.87%
Mar 31, 2019 -26.04%
Dec 31, 2018 -47.04%
Sep 30, 2018 26.00%
Jun 30, 2018 -163,602.71%
Mar 31, 2018 3,433.49%
Dec 31, 2017 70.13%
Sep 30, 2017 13,806.16%
Jun 30, 2017 -62,507.28%
Mar 31, 2017 15,919.65%
Dec 31, 2016 -39,486.19%
Sep 30, 2016 10,539.99%
Jun 30, 2016 88,533.53%
Mar 31, 2016 117,187.42%
Sep 30, 2015 -102,279.52%
Jun 30, 2015 -73.78%
Mar 31, 2015 45.67%
Dec 31, 2014 -154,673.92%
Sep 30, 2014 -8.63%
Jun 30, 2014 10.89%
Mar 31, 2014 -19.10%
Dec 31, 2013 -12.56%
Sep 30, 2013 18.66%
Jun 30, 2013 88.99%
Mar 31, 2013 99.44%
Sep 30, 2012 50.61%
Jun 30, 2012 131.04%
Mar 31, 2012 19.17%